The stock of NuCana plc (NASDAQ:NCNA) is a huge mover today! The stock decreased 11.83% or $0.88 during the last trading session, reaching $6.56. About 167,572 shares traded or 104.05% up from the average. NuCana plc (NASDAQ:NCNA) has declined 57.21% since December 4, 2018 and is downtrending. It has underperformed by 57.21% the S&P500.
The move comes after 8 months negative chart setup for the $212.91M company. It was reported on Dec, 4 by Barchart.com. We have $6.17 PT which if reached, will make NASDAQ:NCNA worth $12.77 million less.
Analysts await NuCana plc (NASDAQ:NCNA) to report earnings on March, 5. They expect $-0.32 EPS, down 128.57 % or $0.18 from last year’s $-0.14 per share. After $-0.15 actual EPS reported by NuCana plc for the previous quarter, Wall Street now forecasts 113.33 % negative EPS growth.
More notable recent NuCana plc (NASDAQ:NCNA) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint – Benzinga” on July 26, 2019, also Seekingalpha.com with their article: “Wall Street Brunch – Seeking Alpha” published on December 01, 2019, Globenewswire.com published: “NuCana plc Announces Withdrawal of Public Offering of ADSs – GlobeNewswire” on January 25, 2019. More interesting news about NuCana plc (NASDAQ:NCNA) were released by: Globenewswire.com and their article: “NuCana plc Announces Proposed Public Offering of ADSs – GlobeNewswire” published on January 23, 2019 as well as Seekingalpha.com‘s news article titled: “NuCana: Improving Standard Chemotherapy Drugs Look Interesting – Seeking Alpha” with publication date: June 12, 2019.
NuCana plc, a biopharmaceutical company, engages in the development of products for the treatment of cancer. The company has market cap of $212.91 million. The firm is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; that is in Phase Ib clinical trials for the treatment of recurrent ovarian cancer; in Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer. It currently has negative earnings. The firm is also developing NUC-3373, which is in Phase I clinical trials for the treatment of patients with advanced solid tumors, as well as for the treatment of colorectal and breast cancer; and NUC-7738, a nucleoside analog that is in preclinical studies for the treatment of solid tumors and hematology.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.